Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress

Abstract

Background3-Hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitors or statins are competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis. Currently, statins are used as first-line therapy in the treatment of diabetic dyslipidemia. However, effects of statins on β cell function remains unclear. This study aims to examine effects of atorvastatin treatment on pancreatic β cell function in obese C57BL/6 J mice and the possible mechanisms.MethodsDiet-induced obesity (DIO) C57BL/6 J mice were treated with atorvastatin (30 mg/kg/day) for 58 days. β cell function was assessed by hyperglycemic clamp and the area of insulin-positive β cells was examined by immunofluorescence. Gene expression was assessed by RT-PCR, and endoplasmic reticulum (ER) stress related proteins were examined by Western blot. Additionally, cell viability and apoptosis of the cholesterol-loaded NIT-1 cells were investigated after atorvastatin treatment.ResultsHyperglycemic clamp study revealed that glucose infusion rate (GIR) and insulin stimulation ratio in atorvastatin-treated DIO mice were markedly higher than control mice (P < 0.05, P < 0.01 vs. con), indicating preserved β-cell sensitivity to glucose. Lipid profiles of plasma triglyceride (TG), pancreas TG and plasma cholesterol (CHO) were improved. Pancreas weight and weight index were improved significantly after atorvastatin treatment (P < 0.05 vs. con). Immunofluorescence results showed that atorvastatin-treated mice had significantly larger insulin-positive β cell area (P < 0.05 vs. con). Furthermore, RT-PCR and western blot showed that the mRNA and protein expression of pancreatic and duodenal homeobox 1 (Pdx1) in the pancreas were upregulated (P < 0.001, P < 0.01 vs. con). Moreover, the expression level of ER stress markers of activating transcription factor 4 (ATF4), CCAAT-enhancer-binding protein homologous protein (CHOP) and phosphorylated eukaryotic initiation factor 2α (eIF2α) were downregulated in the pancreas of atorvastatin-treated mice (P < 0.001, P < 0.01, P < 0.01 vs. con). Besides, atorvastatin protected the pancreatic β cell line of NIT-1 from cholesterol-induced apoptosis. Western blot showed increased expression of anti-apoptotic protein of B-cell lymphoma 2 (Bcl-2).ConclusionPancreatic β cell function of obese C57BL/6 J mice was preserved after atorvastatin treatment, and this improvement may be attributed to enhanced pancreas proliferation and amelioration of pancreatic ER stress.

The additive effects of atorvastatin and insulin on renal function and renal organic anion transporter 3 function in diabetic rats

“…These pleiotropic effects of atorvastatin which led to the adjustment of glucose homeostasis and renoprotection observed in this study might be due to the additive effect of atorvastatin and insulin in controlling metabolic parameters and subsequently protect kidney dysfunction in diabetes. This proposed mechanism is supported by the previous study reporting that atorvastatin can increase β-cell function by increasing β-cell proliferation and decreasing ER stress conditions 33 . The increased insulin secretion and the attenuation of apoptosis of pancreatic tissue seen in rats on the combined treatment in this study reflected an improvement in β-cell function.…”

Therapeutic Effect of Adipose Derived Stem Cells versus Atorvastatin on Amiodarone Induced Lung Injury in Male Rat

“…Comparing the mean values of % of caspase 3 +ve cells in A treated group to AM group, it was significantly decreased. Chen et al ( 32 ) reported decreased apoptotic rate in A treated rats evidenced by flow cytometry analysis. Western blot additionally displayed that atorvastatin induced up regulation of anti-apoptosis protein Bcl-2.…”

Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms

“…Western blot analysis of total protein was performed as previously described [ 13 , 14 ]. Approximately 150 mg of liver, small intestine and kidney tissue were used to extract protein for each assay respectively.…”